Follow
Marc-Andre Gagnon
Marc-Andre Gagnon
School of Public Policy and Admninistration, Carleton University
Verified email at carleton.ca - Homepage
Title
Cited by
Cited by
Year
The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States
MA Gagnon, J Lexchin
Plos medicine 5 (1), e1, 2008
7142008
Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health
MA Gagnon
Journal of Law, Medicine & Ethics 41 (3), 571-580, 2013
1102013
The economic case for universal pharmacare: costs and benefits of publicly funded drug coverage for all Canadians
MA Gagnon, G Hébert
Canadian Centre for Policy Alternatives= Centre canadien de politiques …, 2010
702010
The nature of capital in the knowledge-based economy: The case of the global pharmaceutical industry
MA Gagnon
York University, 2009
572009
Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
D Gleeson, J Lexchin, R Labonté, B Townsend, MA Gagnon, J Kohler, ...
Globalization and Health 15, 1-17, 2019
522019
Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016
MA Gagnon, KD Volesky
Globalization and health 13, 1-7, 2017
442017
CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
J Lexchin, MA Gagnon
Globalization and Health 10, 1-6, 2014
422014
Capital, power and knowledge according to Thorstein Veblen: Reinterpreting the knowledge-based economy
MA Gagnon
Journal of Economic Issues 41 (2), 593-600, 2007
422007
A roadmap to a rational pharmacare policy in Canada
MA Gagnon
Canadian Federation of Nurses Unions, 2014
402014
Mirror, mirror on the wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with US government programs
MA Gagnon, S Wolfe
Carleton University, 2015
292015
New drug pricing: does it make any sense?
MA Gagnon
Prescrire international 24 (162), 192-195, 2015
292015
Combating corruption in the pharmaceutical arena
J Lexchin, JC Kohler, MA Gagnon, J Crombie, P Thacker, A Shnier
Indian J Med Ethics [Internet] 3 (3), 234-9, 2018
242018
Evaluating the effects of Quebec’s private–public drug insurance system
SG Morgan, MA Gagnon, M Charbonneau, A Vadeboncoeur
CMAJ 189 (40), E1259-E1263, 2017
222017
A better prescription: advice for a national strategy on pharmaceutical policy in Canada
SG Morgan, MA Gagnon, B Mintzes, J Lexchin
Healthcare policy 12 (1), 18, 2016
222016
Drug shortages: searching for a cure
MA Gagnon
Healthcare Policy 7 (4), 10, 2012
212012
Recherche clinique sous influence: penser les alternatives
MA Gagnon
Rev Prescrire 32 (342), 311-314, 2012
20*2012
Les réseaux de l’internationalisme statistique (1885-1914)
MA Gagnon
L’ère du chiffre. Systèmes statistiques et traditions nationales, Québec …, 2000
202000
Reforming private drug coverage in Canada: inefficient drug benefit design and the barriers to change in unionized settings
S O’Brady, MA Gagnon, A Cassels
Health Policy 119 (2), 224-231, 2015
162015
Surviving niche busters: main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs
M Charbonneau, MA Gagnon
Health Policy 122 (12), 1295-1301, 2018
132018
Shaping the social determinants of value through economic ghostmanagement: An institutionalist approach to capital accumulation
MA Gagnon
Marx, Veblen, and the Foundations of Heterodox Economics, 250-273, 2015
112015
The system can't perform the operation now. Try again later.
Articles 1–20